MANNKIND CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.31 USD | -2.05% |
|
-1.60% | +18.41% |
| May. 08 | Transcript : MannKind Corporation, Q1 2024 Earnings Call, May 08, 2024 | |
| May. 08 | Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05 | MT |
Presenter SpeechUnknown Analyst (Analysts)Hello, all. Welcome. My name is [ Tousy Kuwash ], an...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.4
USD
Average target price
7.083
USD
Spread / Average Target
+60.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.41% | 1.19B | |
| +2.97% | 108B | |
| +10.21% | 105B | |
| +1.57% | 23.46B | |
| -12.77% | 21.72B | |
| -7.05% | 18.64B | |
| -37.64% | 17.45B | |
| -6.50% | 17.19B | |
| +6.00% | 13.99B | |
| +37.20% | 12.53B |
- Stock Market
- Equities
- MNKD Stock
- News MannKind Corporation
- Transcript : MannKind Corporation Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-12-2023 11